Literature DB >> 17444853

The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers.

Jian-Gao Fan1, Feng Li, Xiao-Bo Cai, Yong-De Peng, Qing-Hong Ao, Yan Gao.   

Abstract

BACKGROUND AND AIM: To evaluate changes in the prevalence rates of ultrasonographic fatty liver (FL) in a specific population.
METHODS: An analysis of the medical records of BaoSteel Group (Shanghai, China) employees was done to evaluate the prevalence of FL in this population, in which health examinations were performed biennially between 1995 and 2002.
RESULTS: The study reviewed a database of 59 131 employees, of which 27.1% received medical check-ups four times within the study period, 26.6% three times, and 24.0% twice. The prevalence rates of obesity and metabolic disorders were high at baseline and increased significantly with time. The prevalence of ultrasonographic FL increased from 3.87% to 14.04% in the overall population, while there was an increase from 4.44% to 14.64% in men and 1.56% to 11.37% in women over the 6-year study period. Increased rates of FL were also noted, from 25.88% to 51.39%, among patients with elevated serum alanine aminotransferase (ALT) levels (> 40 U/L). The highest overall prevalence rates of FL were found in individuals aged 50-60 years, with all age-associated prevalence significantly higher in males than females.
CONCLUSION: The prevalence of FL increased rapidly over the study period with increased rates of obesity and metabolic disorders; FL is becoming a major cause of abnormal ALT levels in the specific population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444853     DOI: 10.1111/j.1440-1746.2007.04892.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  18 in total

1.  Hepatobiliary quiz-7 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-09

2.  Is there any progress in the treatment of non-alcoholic fatty liver disease?

Authors:  Emmanuel A Tsochatzis; George V Papatheodoridis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

Review 3.  The future liver of the Asia pacific: fatter and firmer from more fructose and fortune?

Authors:  Suzanne E Mahady; Jacob George
Journal:  J Clin Exp Hepatol       Date:  2012-12-28

4.  Non-Alcoholic Fatty Liver Disease Is Strongly Associated with Smoking Status and Is Improved by Smoking Cessation in Japanese Males: A Retrospective Study.

Authors:  Haruka Takenaka; Tsuyoshi Fujita; Atsuhiro Masuda; Yoshihiko Yano; Akihiko Watanabe; Yuzo Kodama
Journal:  Kobe J Med Sci       Date:  2020-11-17

5.  Sex hormone affects the severity of non-alcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway.

Authors:  Guangda Xin; Shaoyou Qin; Song Wang; Xu Wang; Yonggui Zhang; Jiangbin Wang
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-18

6.  Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD).

Authors:  Ajay Duseja; Naga Chalasani
Journal:  Hepatol Int       Date:  2013-11-02       Impact factor: 6.047

7.  Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease.

Authors:  Chan Wah-Kheong; Goh Khean-Lee
Journal:  Hepatol Int       Date:  2012-06-15       Impact factor: 6.047

8.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

9.  Alcohol consumption and metabolic syndrome among Shanghai adults: a randomized multistage stratified cluster sampling investigation.

Authors:  Jian-Gao Fan; Xiao-Bu Cai; Lui Li; Xing-Jian Li; Fei Dai; Jun Zhu
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

10.  An exploration of prevalence and associated factors of nonalcoholic Fatty liver disease in the taiwanese police service.

Authors:  Th Tung; Wh Chiu; Th Lin; Hc Shih; Ct Hsu
Journal:  Iran J Public Health       Date:  2011-12-31       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.